Wangang Xie

4.0k total citations · 1 hit paper
34 papers, 1.8k citations indexed

About

Wangang Xie is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Wangang Xie has authored 34 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 18 papers in Epidemiology and 10 papers in Infectious Diseases. Recurrent topics in Wangang Xie's work include Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (10 papers) and Microscopic Colitis (7 papers). Wangang Xie is often cited by papers focused on Hepatitis C virus research (17 papers), HIV/AIDS drug development and treatment (10 papers) and Microscopic Colitis (7 papers). Wangang Xie collaborates with scholars based in United States, Spain and Italy. Wangang Xie's co-authors include Lynn Kuo, Yu Fan, Paul O. Lewis, Ming‐Hui Chen, Edward Tam, Paul Y. Kwo, Carolyn M. Setze, Preethi Krishnan, Thomas Reisch and Daniel E. Cohen and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Wangang Xie

32 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improving Marginal Likelihood Estimation for Bayesian Phylogenetic Model Selection

2010 773 citations Wangang Xie, Paul O. Lewis et al. Systematic Biology profile →

Peers

Wangang Xie

HEPAT

EPIDE

GENET

Dawei Cai China

A J Frodsham United Kingdom

Jiming Zhang China

Melissa D. Conrad United States

Tomoyuki Miura Japan

H. Brünner Austria

Matthew M. Smith United States

Silvia Mascheretti Germany

Yasuo Ina Japan

Pascal Bouffard United States

Dawei Cai China

Wangang Xie

953 ×1.1

HEPAT

1.3k ×1.6

EPIDE

378 ×1.1

450 ×1.3

GENET

571 ×2.0

Citations per year, relative to Wangang Xie Wangang Xie (= 1×) peers Dawei Cai

Countries citing papers authored by Wangang Xie

Since Specialization

Citations

This map shows the geographic impact of Wangang Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wangang Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wangang Xie more than expected).

Fields of papers citing papers by Wangang Xie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wangang Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wangang Xie. The network helps show where Wangang Xie may publish in the future.

Co-authorship network of co-authors of Wangang Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Wangang Xie. A scholar is included among the top collaborators of Wangang Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wangang Xie. Wangang Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rodriguez‐Araujo, Gerardo, et al.. (2024). Safety and efficacy of linaclotide in children aged 2–5 years with functional constipation: Phase 2, randomized study. Journal of Pediatric Gastroenterology and Nutrition. 79(3). 510–518. 2 indexed citations

Khlevner, Julie, Gerardo Rodriguez‐Araujo, Wangang Xie, et al.. (2024). Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet. Gastroenterology & hepatology. 9(3). 238–250. 9 indexed citations

Nurko, Samuel, Gerardo Rodriguez‐Araujo, Wangang Xie, et al.. (2023). 145 EFFICACY AND SAFETY OF LINACLOTIDE IN TREATING FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS AGED 6-17 YEARS: A PHASE 3 PIVOTAL RANDOMIZED PLACEBO-CONTROLLED TRIAL. Gastroenterology. 164(6). S–29. 1 indexed citations

Hyams, Jeffrey S., Miguel Saps, Gerardo Rodriguez‐Araujo, et al.. (2023). Mo2015 SAFETY OF LINACLOTIDE IN PEDIATRIC PATIENTS WITH FUNCTIONAL CONSTIPATION: A POOLED ANALYSIS OF PLACEBO-CONTROLLED RANDOMIZED-CONTROLLED TRIALS. Gastroenterology. 164(6). S–954.

Colombel, Jean‐Frédéric, Julián Panés, Geert D’Haens, et al.. (2020). S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study. The American Journal of Gastroenterology. 115(1). S454–S454. 3 indexed citations

Higgins, Peter, Xavier Hébuterne, Jesse Siffledeen, et al.. (2019). 215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE. The American Journal of Gastroenterology. 114(1). S131–S131. 1 indexed citations

Schnell, Gretja, Preethi Krishnan, Rakesh Tripathi, et al.. (2018). Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS ONE. 13(10). e0205186–e0205186. 10 indexed citations

Zhou, Yijie, Su Chen, Danielle Sullivan, et al.. (2017). Dose-ranging design and analysis methods to identify the minimum effective dose (MED). Contemporary Clinical Trials. 63. 59–66. 7 indexed citations

Kumada, Hiromitsu, Tsunamasa Watanabe, Fumitaka Suzuki, et al.. (2017). Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. Journal of Gastroenterology. 53(4). 566–575. 75 indexed citations

10.

Reau, Nancy, Michael Fried, Heiner Wedemeyer, et al.. (2015). 1013 High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/R, Dasabuvir With or Without Ribavirin for 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials. Gastroenterology. 148(4). S–1002. 1 indexed citations

11.

Colombo, Massimo, Ola Weiland, Daniel E. Cohen, et al.. (2014). SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin. Hepatology. 60. 2 indexed citations

12.

Kwo, Paul Y., Parvez Mantry, Eoin Coakley, et al.. (2014). An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. New England Journal of Medicine. 371(25). 2375–2382. 297 indexed citations

13.

Kowdley, Kris V., Eric Lawitz, Fred Poordad, et al.. (2014). Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. New England Journal of Medicine. 370(3). 222–232. 185 indexed citations

14.

Bernstein, David, Jacob Lalezari, Yan Luo, et al.. (2014). Su1061 Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates≥90% in Treatment-Naïve Adults Infected With Hepatitis C Virus Genotype 1A. Gastroenterology. 146(5). S–977. 1 indexed citations

15.

Poordad, Fred, Kosh Agarwal, Ziad Younes, et al.. (2014). Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study. Clinical Infectious Diseases. 60(4). 608–610. 23 indexed citations

16.

Nahass, Ronald, John M. Vierling, Hans Van Vlierberghe, et al.. (2014). 818Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients, by Baseline Demographics. Open Forum Infectious Diseases. 1(suppl_1). S232–S233.

17.

Lewis, Paul O., et al.. (2013). Posterior Predictive Bayesian Phylogenetic Model Selection. Systematic Biology. 63(3). 309–321. 40 indexed citations

18.

Chen, Ming‐Hui, Baikang Pei, David W. Rowe, et al.. (2011). A Bayesian Approach to Pathway Analysis by Integrating Gene–Gene Functional Directions and Microarray Data. Statistics in Biosciences. 4(1). 105–131. 12 indexed citations

19.

Ge, Miaomiao, L. Kathryn Durham, R. Daniel Meyer, Wangang Xie, & Neal Thomas. (2011). Covariate-Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences. Drug Information Journal. 45(4). 481–493. 28 indexed citations

20.

Xie, Wangang, Paul O. Lewis, Yu Fan, Lynn Kuo, & Ming‐Hui Chen. (2010). Improving Marginal Likelihood Estimation for Bayesian Phylogenetic Model Selection. Systematic Biology. 60(2). 150–160. 773 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact